A Phase II Study of ¹³¹I-rituximab for Patients With Relapsed or Refractory Marginal Zone Lymphoma.

ABSTRACT:

Background

Radioimmunotherapy (RIT) is a rare treatment option for relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). We investigated the safety and efficacy of ¹³¹I-rituximab in patients with relapsed or refractory marginal zone lymphomas.

Methods

Patients with pathologically confirmed marginal zone lymphoma who relapsed or were resistant to prior therapy were enrolled. The patients received 250 mg/m² of unlabeled rituximab immediately before receiving a therapeutic ¹³¹I-rituximab dose. The primary endpoint was the objective response rate (ORR), and the secondary endpoints were toxicity assessment, progression-free survival (PFS), and overall survival (OS).

Results

Ten patients (median age = 57.5 years; range = 32-71) were in

SUBMITTER: Jang YJ 

PROVIDER: S-EPMC10714876 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature